Raul Villarreal, MD
Allergy & Immunology · Live Oak, TXNPI 1083008908
Payments from drug & device makers
Across 607 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Sanofi$2K
- Alk-abello, Inc$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Sanofi-aventis U.S. LLC$1K
- plus $5K from 30 others
What the payments were for
- Grants$7004%
- Travel & lodging$1,55210%
- Food & beverage$13,81785%
- Education$2341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 169 | $2,931 |
| AstraZeneca | 59 | $1,983 |
| Sanofi | 28 | $1,804 |
| Alk-abello, Inc | 27 | $1,656 |
| Regeneron Healthcare Solutions, Inc. | 45 | $1,280 |
| Sanofi-aventis U.S. LLC | 51 | $1,237 |
| CSL Behring | 37 | $755 |
| Pfizer | 38 | $604 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $476 |
| Genentech USA, Inc. | 18 | $461 |
| Intuitive Surgical | 2 | $455 |
| Incyte Corporation | 14 | $298 |
| Grifols USA, LLC | 12 | $244 |
| Biocryst US Sales Co., LLC | 3 | $227 |
| Novartis | 8 | $193 |
| Optinose US, Inc. | 10 | $183 |
| Octapharma USA, Inc. | 9 | $183 |
| Kaleo, Inc. | 10 | $174 |
| Mylan Specialty L.p. | 8 | $165 |
| Blueprint Medicines Corporation | 3 | $147 |
| AbbVie | 7 | $132 |
| Boehringer Ingelheim | 5 | $117 |
| Viatris Specialty LLC | 3 | $81 |
| Galderma Laboratories, L.p. | 2 | $69 |
| Amgen | 3 | $69 |
| Verona Pharma, Inc. | 2 | $60 |
| Genentech, Inc. | 2 | $51 |
| Organon | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $43 |
| Hikma Pharmaceuticals USA | 3 | $42 |
| Lilly USA, LLC | 1 | $31 |
| Pharming Healthcare, Inc. | 1 | $26 |
| Shire North American Group Inc | 2 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dust mite (D. farinae)$1,082
- DUPIXENT$733
- FASENRA$576
- NUCALA$464
- Da Vinci Surgical System$436
- Orladeyo$214
- TRELEGY ELLIPTA$125
- Haegarda$124
- CIBINQO$123
- HYQVIA$122
- XOLAIR$118
- AYVAKIT$114
- AIRSUPRA$108
- TEZSPIRE$108
How this compares
$16,304 in reported general payments places this provider in the 75th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $78,947 |
| Dupixent SyringeDupilumab | 14 | $50,747 |
| Epinephrine | 71 | $14,099 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,484 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,497 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,167 |
| Azelastine Hcl | 34 | $1,131 |
| Fluticasone Propionate | 40 | $860 |
| Ipratropium Bromide | 26 | $521 |
| Levocetirizine Dihydrochloride | 17 | $186 |
| Montelukast Sodium | 30 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $2,931 | $83,443110 claims |
| Hikma Pharmaceuticals USAEpinephrine | $42 | $14,09971 claims |
| AstraZenecaBreztri Aerosphere | $1,983 | $11,48417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 336 allergy & immunology providers in Texas.
Other allergy & immunology in Live Oak
- William HowlandAustin$3.6M
- Russell PerryBeaumont$3.2M
- Barbara BaxterDallas$2.5M
- Lyndon MansfieldEl Paso$2.4M
- Dale MoharKerrville$2.3M
- Erika GonzalezSan Antonio$2.2M
- Richard WassermanDallas$1.9M
- Joseph DiazSan Antonio$1.8M
- Niran AmarWaco$840K
- Robert JacobsSan Antonio$757K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.